{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:20:55Z","timestamp":1790742055081,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Giulio D'Angio Endowed Chair"},{"name":"Patricia Brophy Endowed Chair"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.ijrobp.2019.01.095","type":"journal-article","created":{"date-parts":[[2019,2,10]],"date-time":"2019-02-10T00:45:45Z","timestamp":1549759545000},"page":"401-408","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Outcomes After Proton Therapy for Treatment of Pediatric High-Risk Neuroblastoma"],"prefix":"10.1016","volume":"104","author":[{"given":"Christine E.","family":"Hill-Kayser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zelig","family":"Tochner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goldie","family":"Kurtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Lustig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Balamuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Womer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Mattei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Grupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yael P.","family":"Mosse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Maris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rochelle","family":"Bagatell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2019.01.095_bib1","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S1470-2045(13)70309-7","article-title":"Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): A randomized phase 3 trial","volume":"14","author":"Kreissman","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2019.01.095_bib2","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1056\/NEJMoa0911123","article-title":"Children's Oncology Group. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma","volume":"363","author":"Yu","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2019.01.095_bib3","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0360-3016(02)04506-6","article-title":"Impact of radiotherapy for high-risk neuroblastoma: A Children's Cancer Group study","volume":"56","author":"Haas-Kogan","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.01.095_bib4","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S0360-3016(99)00399-5","article-title":"Local control with multimodality therapy for stage 4 neuroblastoma","volume":"46","author":"Wolden","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.01.095_bib5","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.jpedsurg.2009.11.003","article-title":"Radiation therapy as part of local control of metastatic neuroblastoma: The St Jude Children's Research Hospital experience","volume":"45","author":"Robbins","year":"2010","journal-title":"J Pediatr Surg"},{"key":"10.1016\/j.ijrobp.2019.01.095_bib6","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ijrobp.2012.05.004","article-title":"Results of a quality assurance review of external beam radiation therapy in the International Society of Paediatric Oncology (Europe) Neuroblastoma Group's High-Risk Neuroblastoma Trial: A SIOPEN Study","volume":"85","author":"Gaze","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.01.095_bib7","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1748-717X-6-102","article-title":"Helical tomotherapy in the treatment of pediatric malignancies: A preliminary report of feasibility and acute toxicity","volume":"6","author":"Mesbah","year":"2011","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2019.01.095_bib8","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.ijrobp.2005.03.053","article-title":"The calculated risk of fatal secondary malignancies from intensity-modulated radiation therapy","volume":"62","author":"Kry","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.01.095_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijrobp.2006.01.027","article-title":"Intensity-modulated radiation therapy, protons, and the risk of second cancers","volume":"65","author":"Hall","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.01.095_bib10","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1200\/JCO.2009.24.8062","article-title":"Second malignant neoplasms in survivors of pediatric Hodgkin's lymphoma treated with low-dose radiation and chemotherapy","volume":"28","author":"O'Brien","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2019.01.095_bib11","unstructured":"Fuji H. Proton beam therapy for retroperitoneal neuroblastoma. Abstract presented at the Particle Therapy Cooperative Group 50th Meeting. May 2012; Philadelphia, PA."},{"key":"10.1016\/j.ijrobp.2019.01.095_bib12","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.ijrobp.2011.08.035","article-title":"Proton radiotherapy for high-risk pediatric neuroblastoma: Early outcomes and dose comparison","volume":"83","author":"Hattangadi","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.01.095_bib13","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1002\/pbc.24606","article-title":"Proton versus photon radiation therapy for patients with high-risk neuroblastoma: The need for a customized approach","volume":"60","author":"Hill-Kayser","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ijrobp.2019.01.095_bib14","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/acm2.12012","article-title":"Organ motion in pediatric high-risk neuroblastoma patients using four-dimensional computed tomography","volume":"18","author":"Kannan","year":"2017","journal-title":"J Appl Clin Med Phys"},{"key":"10.1016\/j.ijrobp.2019.01.095_bib15","first-page":"1","article-title":"Prescribing, recording, and reporting proton - beam therapy, ICRU Report, No. 78. (International Commission on Radiation Units and Measurements, Bethesda, MD)","volume":"7","year":"2007","journal-title":"Journal of the ICRU"},{"key":"10.1016\/j.ijrobp.2019.01.095_bib16","doi-asserted-by":"crossref","first-page":"S114","DOI":"10.1016\/j.ijrobp.2014.05.539","article-title":"Extent of lymph node radiation coverage in high-risk neuroblastoma does not affect clinical outcome: A report from the COG A3973 study","volume":"90","author":"Haas-Kogan","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.01.095_bib17","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/pbc.25372","article-title":"Reassessing dose constraints of organs at risk in children with abdominal neuroblastoma treated with definitive radiation therapy: A correlation with late toxicity","volume":"62","author":"Kandula","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ijrobp.2019.01.095_bib18","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.3389\/fimmu.2018.01355","article-title":"A comprehensive safety trial of chimeric antibody 14.18 with GM-CSF, IL-2, and isoretinoin in high-risk neuroblastoma patients following myeloablative therapy: Children\u2019s Oncology Group Study ANBL0931","volume":"9","author":"Ozkaynak","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.ijrobp.2019.01.095_bib19","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1200\/JCO.2008.16.6876","article-title":"The International Neuroblastoma Risk Group (INRG) staging system: An INRG Task Force report","volume":"27","author":"Monclair","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2019.01.095_bib20","first-page":"1","article-title":"Radiobiology with heavy charged particles: A historical review","volume":"14","author":"Skarsgard","year":"1998","journal-title":"Phys Med"},{"key":"10.1016\/j.ijrobp.2019.01.095_bib21","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.ijrobp.2010.07.1989","article-title":"Proton radiotherapy for pediatric bladder\/prostate rhabdomyosarcoma: Clinical outcomes and dosimetry compared to intensity-modulated radiation therapy","volume":"81","author":"Cotter","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.01.095_bib22","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ijrobp.2005.01.060","article-title":"Treatment planning with protons for pediatric retinoblastoma, medulloblastoma, and pelvic sarcoma: How do protons compare with other conformal techniques?","volume":"63","author":"Lee","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.01.095_bib23","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S0360-3016(99)00534-9","article-title":"Late effects in children treated with radiotherapy for Wilms\u2019 tumor","volume":"46","author":"Paulino","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.01.095_bib24","doi-asserted-by":"crossref","first-page":"e264","DOI":"10.1097\/MPH.0b013e3181e7931a","article-title":"Late toxicity in Wilms tumor patients treated with radiotherapy at 15 years of median follow-up","volume":"32","author":"Sasso","year":"2010","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"key":"10.1016\/j.ijrobp.2019.01.095_bib25","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/(SICI)1096-911X(199911)33:5<462::AID-MPO5>3.0.CO;2-8","article-title":"Hepatotoxicity in patients treated according to the nephroblastoma trial and study SIOP-9\/GPOH","volume":"33","author":"Ludwig","year":"1999","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.ijrobp.2019.01.095_bib26","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/bmt.2013.218","article-title":"Late effects in children treated with intensive multimodal therapy for high-risk neuroblastoma: High incidence of endocrine and growth problems","volume":"49","author":"Cohen","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ijrobp.2019.01.095_bib27","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.ijrobp.2004.11.038","article-title":"Predicting age of ovarian failure after radiation to a field that includes the ovaries","volume":"62","author":"Wallace","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.01.095_bib28","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1007\/s00066-015-0837-z","article-title":"Long-term side effects of radiotherapy for pediatric localized neuroblastoma","volume":"191","author":"Ducassou","year":"2015","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.ijrobp.2019.01.095_bib29","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ijrobp.2016.05.020","article-title":"Local control with 21-Gy radiation therapy for high-risk neuroblastoma","volume":"96","author":"Casey","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.01.095_bib30","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.ijrobp.2016.11.043","article-title":"Favorable local control from consolidative radiation therapy in high-risk neuroblastoma despite gross residual disease, positive margins, or nodal involvement","volume":"97","author":"Ferris","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2019.01.095_bib31","doi-asserted-by":"crossref","first-page":"e27009","DOI":"10.1002\/pbc.27009","article-title":"Dose-escalation is needed for gross disease in high-risk neuroblastoma","volume":"65","author":"Casey","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ijrobp.2019.01.095_bib32","doi-asserted-by":"crossref","first-page":"e417","DOI":"10.1016\/j.prro.2015.06.001","article-title":"Factors associated with event reporting in the pediatric radiation oncology population using an electronic incident reporting system","volume":"5","author":"Hill-Kayser","year":"2015","journal-title":"Pract Radiat Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301619301907?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301619301907?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T09:43:45Z","timestamp":1759743825000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301619301907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0360301619301907"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2019.01.095","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes After Proton Therapy for Treatment of Pediatric High-Risk Neuroblastoma","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2019.01.095","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}